ESMO 2021
VGEF antibody plus TKI: the conundrum continues
230 videos online
ESMO 2021
Daniel Shao-Weng Tan, MD
VGEF antibody plus TKI: the conundrum continues
BEVERLY, WJOG971L
ESMO 2021
Javier Cortes, MD
T-Dxd - a new standard for 2nd line HER2+ MBC
Destiny-Breast03
ESMO 2021
Hope Rugo, MD
T-Dxd: New treatment paradigm for patients with…
DESTINY-Breast03
ESMO 2021
Sara Tolaney, MD
First study to report OS benefit with CDK4/6i in first…
MONALEESA-02:
ESMO 2021
Tom Powles, MD
ESMO highlights: Spacing out Ipi; TKI drug holidays,…
PRISM, STAR, KEYNOTE-564
ESMO 2021
Georgina Long, MD
My ESMO melanoma highlights
KEYNOTE-716, RELATIVITY-047, COLUMBUS
ESMO 2021
Eleni Efstathiou MD
The game changer: Abiraterone in high risk M0 prostate…
STAMPEDE
ESMO 2021
Marc-Oliver Grimm, MD
Long-term survival with double checkpoint-inhibition
CheckMate-214
ESMO 2021
Axel Hauschild, MD
Pembrolizumab adjuvant in stage II reduces the risk of…
KEYNOTE-716
Hope Rugo, MD
ESMO 2021
T-Dxd: New treatment paradigm for patients with metastatic HER2+ breast cancer
Sara Tolaney, MD
ESMO 2021
First study to report OS benefit with CDK4/6i in first line setting for postmenopausal patients
Eleni Efstathiou MD
ESMO 2021
The game changer: Abiraterone in high risk M0 prostate cancer
Axel Hauschild, MD
ESMO 2021
Pembrolizumab adjuvant in stage II reduces the risk of recurrence, but long-term side effects are possible
Abstract: LBA3
ESMO 2021
M. Untch, N. Harbeck, B. Pistilli, A. Gennari, J. Cortes, G. Curigliano, S. Tolaney
DESTINY Breast03: T-Dxd - a new standard for HER2+ MBC
DESTINY-Breast03
ESMO 2021
V. Müller, N. Harbeck, B. Pistilli, A. Gennari, J. Cortes, G. Curigliano, S. Tolaney
KEYNOTE-355: Pembrolizumab A new option for TNBC
KEYNOTE-355
ESMO 2021
M. Untch, V. Müller, N. Harbeck, A. Gennari, S. Tolaney, J. Cortes, B. Pistilli, G. Curigliano
MONALEESA-2: Long Term 1st Line significant overall…
MONALEESA-02
M. Untch, N. Harbeck, B. Pistilli, A. Gennari, J. Cortes, G. Curigliano, S. Tolaney
ESMO 2021
DESTINY Breast03: T-Dxd - a new standard for HER2+ MBC
V. Müller, N. Harbeck, B. Pistilli, A. Gennari, J. Cortes, G. Curigliano, S. Tolaney
ESMO 2021
KEYNOTE-355: Pembrolizumab A new option for TNBC
M. Untch, V. Müller, N. Harbeck, A. Gennari, S. Tolaney, J. Cortes, B. Pistilli, G. Curigliano
ESMO 2021
MONALEESA-2: Long Term 1st Line significant overall survival with ribociclib
ESMO 2021
Peter A. Fasching, MD
Ribociclib in 1st line: Long follow-up time confirms OS…
MONALEESA-2
ESMO 2021
Hope Rugo, MD
T-Dxd: New treatment paradigm for patients with…
DESTINY-Breast03
ESMO
Michael Untch, MD
Two positive trials reinforce the role of…
KEYNOTE355, KEYNOTE-522
ESMO 2021
Barbara Pistilli, MD
Impressive new data on the improvement of PFS with…
Destiny-Breast03
ESMO 2021
Peter A. Fasching, MD
T-DXd: Impressive results show the potential of ADC…
DESTINY-Breast03
ESMO 2021
Javier Cortes, MD, PhD
T-Dxd - a new standard for 2nd line HER2+ MBC
Destiny-Breast03
ESMO 2021
Giuseppe Curigliano, MD
ESMO21 highlights in metastatic and early breast cancer
DESTINY-BREAST03, KEYNOTE-355, BrightNess
ESMO 2021
Volkmar Müller, MD
Management of Carcinomatous Meningitis (CM) in breast…
Carcinomatous Meningitis
ESMO 2021
Volkmar Müller, MD
Great results and further research
DESTINY-BREAST03, DEBRAH, DESTINY-Breast12, TUXEDO-1
ESMO 2021
Sara Tolaney, MD
Survival data confirm pembrolizumab as standard of care
KEYNOTE-355
ESMO 2021
Sara Tolaney, MD
First study to report OS benefit with CDK4/6i in first…
MONALEESA-02:
ESMO 2021
Elzbieta Senkus-Konefka, MD
Large step forward in HER2+ MBC with T-Dxd
DESTINY-Breast03
ESMO 2021
Elzbieta Senkus-Konefka, MD
Finally a survival benefit in 1st line metastatic TNBC
KEYNOTE-355
ESMO 2021
Gil Morgan, MD
Becoming the standard of care for patients with HER2+…
DESTINY-Breast03
ESMO 2021
Karen Gelmon, MD
MBC significant data: T-Dxd, Pembrolizumab, Ribciclib
KEYNOTE-355, DESTINY Breast03, MONALEESA-2
ESMO 2021
Michael Untch, MD
Remarkable survival benefit with Ribociclib defines a…
Monaleesa-02
Peter A. Fasching, MD
ESMO 2021
Ribociclib in 1st line: Long follow-up time confirms OS advantage
Abstract: LBA17
Hope Rugo, MD
ESMO 2021
T-Dxd: New treatment paradigm for patients with metastatic HER2+ breast cancer
Michael Untch, MD
ESMO
Two positive trials reinforce the role of Checkpoint-inhibitors in early and metastatic TNBC
Barbara Pistilli, MD
ESMO 2021
Impressive new data on the improvement of PFS with T-Dxd in patients Her2+ mBC
Peter A. Fasching, MD
ESMO 2021
T-DXd: Impressive results show the potential of ADC technology
Abstract: LBA1
Volkmar Müller, MD
ESMO 2021
Management of Carcinomatous Meningitis (CM) in breast cancer patients
Abstract: 311P
Volkmar Müller, MD
ESMO 2021
Dose escalation of everolimus in patients with metastatic breast cancer (mBC)
Abstract: LBA19
Sara Tolaney, MD
ESMO 2021
First study to report OS benefit with CDK4/6i in first line setting for postmenopausal patients
Elzbieta Senkus-Konefka, MD
ESMO 2021
Finally a survival benefit in 1st line metastatic TNBC
Michael Untch, MD
ESMO 2021
Remarkable survival benefit with Ribociclib defines a new standard of care for patients with HR+ mBC
ESMO 2021
Peter A. Fasching, MD
Ribociclib in 1st line: Lange Nachbeobachtungszeit…
MONALEESA-2
ESMO 2021
Elzbieta Senkus-Konefka, MD
Nareszcie wydłużenie całkowitego czasu przeżycia w 1.…
KEYNOTE-355
ESMO 2021
Michael Untch, MD
Beneficiu ramarcabil cu Ribociclib in prima linie de…
Monaleesa-02
ESMO 2021
Michael Untch, MD
Doua trialuri pozitive in tratamentului imunoonologic…
KEYNOTE355, KEYNOTE-522
ESMO 2021
Barbara Pistilli, MD
Dés résultats impressionnants avec les T-DXd en 2ème…
Destiny-Breast03
ESMO 2021
Barbara Pistilli, MD
Risultati straordinari con il T-DXd in seconda linea…
Destiny-Breast03
ESMO 2021
Peter A. Fasching, MD
T-DXd: Beeindruckende Ergebnisse zeigen Potenzial der…
DESTINY-Breast03
ESMO 2021
Javier Cortes, MD, PhD
T-DXd: un nuevo estándar de tratamiento en pacientes…
Destiny-Breast03
ESMO 2021
Giuseppe Curigliano, MD
Punti salienti nel carcinoma mammario metastatico e…
DESTINY-BREAST03, KEYNOTE-355, BrightNess
ESMO 2021
Elzbieta Senkus-Konefka, MD
Krok milowy w leczeniu zaawansowanego, HER2-dodatniego…
DESTINY-Breast03
Peter A. Fasching, MD
ESMO 2021
Ribociclib in 1st line: Lange Nachbeobachtungszeit bestätigt OS-Vorteil
Abstract: LBA17
Elzbieta Senkus-Konefka, MD
ESMO 2021
Nareszcie wydłużenie całkowitego czasu przeżycia w 1. linii leczenia zaawansowanego, potrójnie ujemnego raka piersi - KEYNOTE-355
Michael Untch, MD
ESMO 2021
Beneficiu ramarcabil cu Ribociclib in prima linie de tratatment , nou standard la paciente cu cancer mamar metastatic HR+, Her -
Michael Untch, MD
ESMO 2021
Doua trialuri pozitive in tratamentului imunoonologic cu pembrolizumab la pacientele cu cancer mamar timpuriu si metastatic triplu negativ
Barbara Pistilli, MD
ESMO 2021
Dés résultats impressionnants avec les T-DXd en 2ème ligne chez les patientes atteintes d’un cancer HER2-positif métastatique
Abstract: LBA1
Barbara Pistilli, MD
ESMO 2021
Risultati straordinari con il T-DXd in seconda linea nelle pazienti con tumore della mammella metastatico HER2 positivo
Abstract: LBA1
Peter A. Fasching, MD
ESMO 2021
T-DXd: Beeindruckende Ergebnisse zeigen Potenzial der ADC-Technologie
Abstract: LBA1
Javier Cortes, MD, PhD
ESMO 2021
T-DXd: un nuevo estándar de tratamiento en pacientes con cáncer de mama metastásica HER2 en segunda línea
Abstract: LBA1
Elzbieta Senkus-Konefka, MD
ESMO 2021
Krok milowy w leczeniu zaawansowanego, HER2-dodatniego raka piersi
ESMO 2021
R. Dent, K. Gelmon, E. Senkus-Konefka, V. Müller, M. Untch, H. Rugo
TNBC: Carboplatinum in neoadjuvant therapy
BrighTNess
ESMO 2021
R. Dent, K. Gelmon, E. Senkus-Konefka, V. Müller, M. Untch, H. Rugo
HER2+: Reduced duration of adjuvant Trastuzumab
HER2+ Meta-Analyses
ESMO 2021
R. Dent, K. Gelmon, E. Senkus-Konefka, V. Müller, M. Untch, H. Rugo
TNBC: CPI performing in the neo-adjuvant setting
KEYNOTE-522
R. Dent, K. Gelmon, E. Senkus-Konefka, V. Müller, M. Untch, H. Rugo
ESMO 2021
TNBC: Carboplatinum in neoadjuvant therapy
R. Dent, K. Gelmon, E. Senkus-Konefka, V. Müller, M. Untch, H. Rugo
ESMO 2021
HER2+: Reduced duration of adjuvant Trastuzumab
R. Dent, K. Gelmon, E. Senkus-Konefka, V. Müller, M. Untch, H. Rugo
ESMO 2021
TNBC: CPI performing in the neo-adjuvant setting
Abstract: VP7_2021
ESMO 2021
Karen Gelmon, MD
TNBC Benefit: Pembro + NACT; Carboplatinum
KEYNOTE-522, BrighTNess
ESMO 2021
Nadia Harbeck, MD
Patient selection allows efficacy and deescalation
WSG ADAPT TP
ESMO 2021
Nadia Harbeck, MD
Trastuzumab + Lapatinib; reducing the duration of…
HER2 - Metaanalysen
ESMO 2021
Alessandra Gennari, MD, PhD
Extended adjuvant Letrozole with significant DFS…
GIM4
ESMO 2021
Alessandra Gennari, MD, PhD
Addition of Carbo-Platin with signifcant EFS advantage
BrighTNess
ESMO 2021
Peter A. Fasching, MD
Neoadjuvant Giredestrant showed anti-proliverative…
coopERA BC
ESMO 2021
Elzbieta Senkus-Konefka, MD, PhD
Carboplatin, a new standard of care in early TNBC?
BrighTNess
Nadia Harbeck, MD
ESMO 2021
Patient selection allows efficacy and deescalation
Abstract: LBA13
Nadia Harbeck, MD
ESMO 2021
Trastuzumab + Lapatinib; reducing the duration of anti-HER2 treatment
Alessandra Gennari, MD, PhD
ESMO 2021
Extended adjuvant Letrozole with significant DFS benefit
Alessandra Gennari, MD, PhD
ESMO 2021
Addition of Carbo-Platin with signifcant EFS advantage
Peter A. Fasching, MD
ESMO 2021
Neoadjuvant Giredestrant showed anti-proliverative effect
Abstract: LBA14
Elzbieta Senkus-Konefka, MD, PhD
ESMO 2021
Carboplatin, a new standard of care in early TNBC?
ESMO 2021
Peter A. Fasching, MD
Verkürzung der Trastuzumab-Therapie auf 6 Monate?
ESMO 2021
ESMO 2021
Alessandra Gennari, MD, PhD
Aggiunta di carboplatino neoadiuvante con vantaggio…
BrighTNess
ESMO 2021
Alessandra Gennari, MD, PhD
Estensione del letrozolo adiuvante con vantaggio…
GIM4
ESMO 2021
Peter A. Fasching, MD
Giredestrant zeigt anti-proliverative Wirkung im…
coopERA BC
ESMO 2021
Elzbieta Senkus-Konefka, MD, PhD
Karboplatyna – nowy standard leczenia we wczesnym,…
BrighTNess
ESMO 2021
Nadia Harbeck, MD
Trastuzumab: Kombination mit Lapatinib und verkürzte…
HER2 - Metaanalysen
Alessandra Gennari, MD, PhD
ESMO 2021
Aggiunta di carboplatino neoadiuvante con vantaggio significativo in DFS
Alessandra Gennari, MD, PhD
ESMO 2021
Estensione del letrozolo adiuvante con vantaggio significativo in DFS
Peter A. Fasching, MD
ESMO 2021
Giredestrant zeigt anti-proliverative Wirkung im neoadjuvanten Setting
Abstract: LBA14
Elzbieta Senkus-Konefka, MD, PhD
ESMO 2021
Karboplatyna – nowy standard leczenia we wczesnym, potrójnie ujemnym raku piersi?
Nadia Harbeck, MD
ESMO 2021
Patientenselektion mit hoher Wirksamkeit und Deeskalation zugleich
Nadia Harbeck, MD
ESMO 2021
Trastuzumab: Kombination mit Lapatinib und verkürzte HER2- Blockade
ESMO 2021
F. Griesinger, M. Reck, M. Thomas, N. Reguart, N. Girard, A. Addeo, D. SW Tan, M. Hellmann, H. Borghaei
BFAST: The Challenge of new biomarkers for…
BFAST
ESMO 2021
F. Griesinger, M. Reck, M. Thomas, N. Reguart, N. Girard, A. Addeo, D. SW Tan, M. Hellmann, H. Borghaei
Upcoming therapy options in oncogenic-driven NSCLC
DESTINY-Lung01, TROPION, ZENITH20-4
ESMO 2021
F. Griesinger, M. Reck, M. Thomas, N. Reguart, N. Girard, A. Addeo, D. SW Tan, M. Hellmann, H. Borghaei
IO combinations in advanced NSCLC - revolution and…
EMPOWER-Lung 3, POSEIDON, other
F. Griesinger, M. Reck, M. Thomas, N. Reguart, N. Girard, A. Addeo, D. SW Tan, M. Hellmann, H. Borghaei
ESMO 2021
BFAST: The Challenge of new biomarkers for immunotherapy
Abstract: 1281O
ESMO 2021
Noemi Reguart, MD, PhD
New options for 2nd line after IO-failure
Atalante-1, MRTX-500
ESMO 2021
Lizza Hendriks, MD
KRASG12C and platinum doublet chemotherapy: does the…
NVALT22
ESMO 2021
Noemi Reguart, MD, PhD
New options in salvage setting for EGFR-mutant patients
TROPION-PanTumor01, CHRYSALIS, CHRYSALIS-2
ESMO 2021
Matthew D. Hellmann, MD
New opportunitiy to treat HER2-mutated lung cancer
DESTINY-Lung01
ESMO 2021
Daniel Shao-Weng Tan, PhD
VGEF antibody plus TKI: the conundrum continues
BEVERLY, WJOG971L
ESMO 2021
Frank Griesinger, MD, PhD
Cemiplimab + chemotherapy: 1st presentation of…
EMPOWER-Lung3
ESMO 2021
Michael Thomas, MD
HER2 mutations: new opportunities effective
DESTINY-Lung01, ZENITH20-4
ESMO 2021
Nicolas Girard, MD
Trastuzumab Deruxtecan, a new option for HER2+ lung…
DESTINY-Lung01
ESMO 2021
Denis Moro-Sibilot, MD
Failure to demonstrate PFS-improvement when combining…
WJOG9717L study
Lizza Hendriks, MD
ESMO 2021
Are vaccines the way forward after progressing on immunotherapy?
Abstract: LBA47
Lizza Hendriks, MD
ESMO 2021
KRASG12C and platinum doublet chemotherapy: does the backbone matter?
Abstract: LBA50
Frank Griesinger, MD, PhD
ESMO 2021
Cemiplimab + chemotherapy: 1st presentation of EMPOWER-Lung3 data
Abstract: LBA51
Christian Grohé, MD
ESMO 2021
Gavo-cel dose escalation in refractory mesothelin-expressing solid tumors
Nicolas Girard, MD
ESMO 2021
Trastuzumab Deruxtecan, a new option for HER2+ lung cancer
Denis Moro-Sibilot, MD
ESMO 2021
Failure to demonstrate PFS-improvement when combining bevacicumab and osimertinib
ESMO 2021
Noemi Reguart, MD, PhD
Nuevas terapias en linea avanzada de pacientes con…
TROPION-PanTumor01, CHRYSALIS, CHRYSALIS-2
ESMO 2021
Denis Moro-Sibilot, MD
Un nouveau traitement pour le CBNPC HER2-muté
DESTINY-Lung01
ESMO 2021
Noemi Reguart, MD, PhD
Nuevas opciones terapéuticas en segunda linea tras…
Atalante-1, MRTX-500
ESMO 2021
Frank Griesinger, MD, PhD
Cemilimab + Chemotherapie: Erste Daten der…
EMPOWER-Lung3
ESMO 2021
Michael Thomas, MD
HER2 Mutation: Drug-Immuno-Conjugates effektiv
DESTINY-Lung01, ZENITH20-4
ESMO 2021
Nicolas Girard, MD
le TdxD, nouvelle option pour les CBNPC HER2+?
DESTINY-Lung01
ESMO 2021
Denis Moro-Sibilot, MD
Absence d'amélioration de la SSP en associant le…
Étude WJOG9717L
Christian Grohé, MD
ESMO 2021
CAR-T-Zell-Therapie auch bei refraktären Karzinompatienten?
Abstract: 959O
Frank Griesinger, MD, PhD
ESMO 2021
Cemilimab + Chemotherapie: Erste Daten der EMPOWER-Lung3
Abstract: LBA51
Michael Thomas, MD
ESMO 2021
Chemoimmuntherapie 1st line: Wohin führt POSEIDON?
abstract: WCLC: PL02.01
Denis Moro-Sibilot, MD
ESMO 2021
Absence d'amélioration de la SSP en associant le bevacicumab et l'osimertinib
ESMO 2021
F. Griesinger, M. Reck, M. Thomas, N. Reguart, S. Liu, L. Hendriks, D. Moro-Sibilot
Stage III NSCLC - the new stage IV ?!
COAST, PACIFIC-R
ESMO 2021
F. Griesinger, M. Reck, M. Thomas, N. Reguart, S. Liu, L. Hendriks, D. Moro-Sibilot
Immune checkpoint inhibitors - on the way to standard…
IMpower010, IONESCO
F. Griesinger, M. Reck, M. Thomas, N. Reguart, S. Liu, L. Hendriks, D. Moro-Sibilot
ESMO 2021
Stage III NSCLC - the new stage IV ?!
F. Griesinger, M. Reck, M. Thomas, N. Reguart, S. Liu, L. Hendriks, D. Moro-Sibilot
ESMO 2021
Immune checkpoint inhibitors - on the way to standard therapy in early stage NSCLC
ESMO 2021
Stephen Liu, MD
Update on chemoradiation for stage III NSCLC
PACIFIC-R, COAST, GEMSTONE-301
ESMO 2021
Frank Griesinger, MD, PhD
Endpoint pathological response in induction therapy…
IONESCO
ESMO 2021
Michael Thomas, MD
IO mono-Induction: window of opportunity to guide…
IONESCO, LCMC3
ESMO 2021
Denis Morot-Sibilot, MD
Immunotherapy improves PFS after sequential or…
GEMSTONE-301
ESMO 2021
Matthew D. Hellmann, MD
Inflection point in next generation drug development
GEMSTONE-301
Stephen Liu, MD
ESMO 2021
Update on chemoradiation for stage III NSCLC
Frank Griesinger, MD, PhD
ESMO 2021
Endpoint pathological response in induction therapy with immun checkpoint inhibition
Abstract: 1151MO
Denis Morot-Sibilot, MD
ESMO 2021
Immunotherapy improves PFS after sequential or concomittant radiochemotherapy
Matthew D. Hellmann, MD
ESMO 2021
Inflection point in next generation drug development
ESMO 2021
Lizza Hendriks, MD
KRASG12C en platinum doublet chemotherapie: maakt de…
NVALT22
ESMO 2021
Michael Thomas, MD
IO Mono Induktion - Zeitfenster für Immuntherapie
IONESCO, LCMC3
ESMO 2021
Nicolas Girard, MD
Quelle efficacité du durvalumab en pratique clinique?
PACIFIC-R
ESMO 2021
Denis Morot-Sibilot, MD
L'immunothérapie améliore la SSP après une…
GEMSTONE-301
Lizza Hendriks, MD
ESMO 2021
Zijn vaccins de toekomst na progressie op immunotherapie?
Abstract: LBA47
Lizza Hendriks, MD
ESMO 2021
Postoperatie radiotherapie bij N2 ziekte: is de discussie nu echt gesloten?
Abstract: 1170O
Lizza Hendriks, MD
ESMO 2021
KRASG12C en platinum doublet chemotherapie: maakt de combinatie wat uit?
Abstract: LBA50
Frank Griesinger, MD, PhD
ESMO 2021
Pathological Response als Endpunkt bei Induktionstherapie mit immuncheckpoint-Inhibition
Abstract: 1151MO
Michael Thomas, MD
ESMO 2021
IO Mono Induktion - Zeitfenster für Immuntherapie
zum Abstract 1151MO WCLC: MA09.01
Nicolas Girard, MD
ESMO 2021
Quelle efficacité du durvalumab en pratique clinique?
Denis Morot-Sibilot, MD
ESMO 2021
L'immunothérapie améliore la SSP après une radiochimiothérapie séquentielle ou concomitante
ESMO 2021
Noemi Reguart, MD, PhD
Update on important phase III trials
Checkmate 743, CASPIAN
ESMO 2021
Noemi Reguart, MD, PhD
Actualizaciones en estudios fase III
Checkmate743, CASPIAN
ESMO 2021
F. Griesinger, M. Reck, M. Thomas, N. Reguart, N. Girard, A. Addeo, D. SW Tan, M. Hellmann, H. Borghaei
NIVOTHYM: Immunotherapy for thymic tumors
NIVOTHYM
F. Griesinger, M. Reck, M. Thomas, N. Reguart, N. Girard, A. Addeo, D. SW Tan, M. Hellmann, H. Borghaei
ESMO 2021
NIVOTHYM: Immunotherapy for thymic tumors
Abstract: LBA66
ESMO 2021
Nicolas Girard, MD
Is there a role for immunotherapy for thymic tumors?
NIVOTHYM
Nicolas Girard, MD
ESMO 2021
Is there a role for immunotherapy for thymic tumors?
Nicola Girard, MD
ESMO 2021
Quelle place de l’immunothérapie pour les tumeurs thymiques? Essai NIVOTHYM
ESMO 2021
F. Griesinger, M. Reck, M. Thomas, N. Reguart, S. Liu, L. Hendriks, D. Moro-Sibilot
New era in mesothelioma – stay tuned!
Checkmate 743, NCT02856425
F. Griesinger, M. Reck, M. Thomas, N. Reguart, S. Liu, L. Hendriks, D. Moro-Sibilot
ESMO 2021
New era in mesothelioma – stay tuned!
ESMO 2021
Noemi Reguart, MD, PhD
Update on important phase III trials
Checkmate 743, CASPIAN
ESMO 2021
Noemi Reguart, MD, PhD
Actualizaciones en estudios fase III
Checkmate743, CASPIAN
ESMO 2021
A. Hauschild, G. Long, R. Dummer, P. Ascierto, D. Schadendorf, M. Postow, P. Nathan
RELATIVITY-047: Subgroup updates; Enduring benefit and…
RELATIVITY-047
ESMO 2021
A. Hauschild, G. Long, R. Dummer, P. Ascierto, D. Schadendorf, M. Postow, P. Nathan
CheckMate 204: Brain metastases - Promising…
CheckMate 204, GEM1802/EBRAIN-MEL
ESMO 2021
A. Hauschild, G. Long, R. Dummer, P. Ascierto, D. Schadendorf, M. Postow, P. Nathan
New data for BRAF-mutated melanoma patients
COLUMBUS, SECOMBIT
ESMO 2021
A. Hauschild, G. Long, R. Dummer, P. Ascierto, D. Schadendorf, M. Postow, P. Nathan
KEYNOTE-716: Adjuvant pembrolizumab in stage IIB/C
KEYNOTE-716
ESMO 2021
A. Hauschild, G. Long, R. Dummer, P. Ascierto, D. Schadendorf, M. Postow, P. Nathan
MASTERKEY-265: Pembrolizumab +/- T-VEC
MASTERKEY-265
A. Hauschild, G. Long, R. Dummer, P. Ascierto, D. Schadendorf, M. Postow, P. Nathan
ESMO 2021
RELATIVITY-047: Subgroup updates; Enduring benefit and prolonged PFS2
Zum Abstract: 1036O
A. Hauschild, G. Long, R. Dummer, P. Ascierto, D. Schadendorf, M. Postow, P. Nathan
ESMO 2021
KEYNOTE-716: Adjuvant pembrolizumab in stage IIB/C
Abstract: LBA3
A. Hauschild, G. Long, R. Dummer, P. Ascierto, D. Schadendorf, M. Postow, P. Nathan
ESMO 2021
MASTERKEY-265: Pembrolizumab +/- T-VEC
Abstract: 1037O
ESMO 2021
Georgina Long, MD
My ESMO melanoma highlights
KEYNOTE-716, RELATIVITY-047, COLUMBUS
ESMO 2021
Michael Postow, MD
Additional efficacy and shifts in treatment options
RELATIVITY-047
ESMO 2021
Dirk Schadendorf, MD
Pembrolizumab is a good option for adjuvant stage IIB/C
KEYNOTE-716
ESMO 2021
Dirk Schadendorf, MD
LAG-3-blocking ab shows benefit in combination with…
RELATIVITY-047
ESMO 2021
Axel Hauschild, MD
Pembrolizumab adjuvant in stage II reduces the risk of…
KEYNOTE-716
ESMO 2021
Paul Nathan, PhD
First data using immunotherapy as an adjuvant mechanism…
KEYNOTE-716
ESMO 2021
Paul Nathan, PhD
Personalized treatment for patients according to IFN-γ…
DONIMI
Dirk Schadendorf, MD
ESMO 2021
Pembrolizumab is a good option for adjuvant stage IIB/C
Abstract: LBA3
Dirk Schadendorf, MD
ESMO 2021
LAG-3-blocking ab shows benefit in combination with Nivo
Abstract: 1036O
Axel Hauschild, MD
ESMO 2021
Pembrolizumab adjuvant in stage II reduces the risk of recurrence, but long-term side effects are possible
Abstract: LBA3
Paul Nathan, PhD
ESMO 2021
First data using immunotherapy as an adjuvant mechanism in stage II
Abstract: LBA3
Paul Nathan, PhD
ESMO 2021
Personalized treatment for patients according to IFN-γ sign
Abstract: LBA39
ESMO 2021
Axel Hauschild, MD
Pembro adj. im Stad. II verringert Rezidivrisiko, aber…
KEYNOTE-716
ESMO 2021
A. S. Merseburger, M.-O. Grimm, S. Chowdhury, I. Duran, H. Hammers, S. K. Pal, T. Powles
PRO results support adjuvant IO efficacy, some…
KEYNOTE-564
ESMO 2021
M.-O. Grimm, P. J. Goebell, S. Chowdhury, I. Duran, H. Hammers, S. K. Pal, T. Powles
Maintaining the IO-combination with higher flexibility.
PRISM/CheckMate 214
A. S. Merseburger, M.-O. Grimm, S. Chowdhury, I. Duran, H. Hammers, S. K. Pal, T. Powles
ESMO 2021
PRO results support adjuvant IO efficacy, some questions still open!
M.-O. Grimm, P. J. Goebell, S. Chowdhury, I. Duran, H. Hammers, S. K. Pal, T. Powles
ESMO 2021
Maintaining the IO-combination with higher flexibility.
ESMO 2021
Tom Powles, MD
ESMO highlights: Spacing out Ipi; TKI drug holidays,…
PRISM, STAR, KEYNOTE-564
ESMO 2021
Marc-Oliver Grimm, MD
Long-term survival with double checkpoint-inhibition
CheckMate-214
ESMO 2021
Marc-Oliver Grimm, MD
Role of cytoreductive nephrectomy in patients treated…
JAVELIN-renal101
Marc-Oliver Grimm, MD
ESMO 2021
Role of cytoreductive nephrectomy in patients treated with TKI/IO combination
Peter Goebell, MD
ESMO 2021
Increased flexibility for side effects due to ipilimumab
ESMO 2021
Axel S. Merseburger, MD
Spannende Daten, wenn auch nicht "game-changing"
KEYNOTE-564
ESMO 2021
Peter Goebell, MD
Höhere Flexibilität bei Nebenwirkungen durch Ipilimumab
PRISM
ESMO 2021
M.-O. Grimm, P. J. Goebell, Y. Loriot, J. Bellmunt, S. Chowdhury
VESPER: Do we have to intensify perioperative…
ESMO 2021
M.-O. Grimm, P. J. Goebell, Y. Loriot, J. Bellmunt, S. Chowdhury
NABUCCO: IPI matters – discussion on benefits in…
M.-O. Grimm, P. J. Goebell, Y. Loriot, J. Bellmunt, S. Chowdhury
ESMO 2021
VESPER: Do we have to intensify perioperative chemotherapy in bladder cancer?
Abstract: 652O
M.-O. Grimm, P. J. Goebell, Y. Loriot, J. Bellmunt, S. Chowdhury
ESMO 2021
NABUCCO: IPI matters – discussion on benefits in bladder cancer
Abstract: LBA31
ESMO 2021
Petros Grivas, MD, PhD
VESPER neoadjuvant chemotherapy phase 3 trial in MIBC
VESPER
ESMO 2021
Andrea Necchi, MD
ESMO21:The highlights of Bladder cancer
VESPER, AURA, NABUCCO, NORSE
ESMO 2021
Tom Powles, MD
ESMO highlights: new combinations FGFRa, Pembro+sEphB4,…
NORSE, VESPER
ESMO 2021
Joaquim Bellmunt, MD, PhD
Improving patients outcome in bladder cancer
NORSE, VESPER, Phase II Pembrolizumab in combination with sEphB4-HSA (B4)
ESMO 2021
Joaquim Bellmunt, MD, PhD
Deciphering strategies for immunotherapy combinations
IMvigor130, AURA, NABUCCO
ESMO 2021
Joaquim Bellmunt, MD, PhD
PD-L1 as predictor of survival in DANUBE phase III…
DANUBE
Petros Grivas, MD, PhD
ESMO 2021
VESPER neoadjuvant chemotherapy phase 3 trial in MIBC
Abstract: 652O
Peter Goebell, MD
ESMO 2021
ipilimumab-nivolumab opportunities for alternative regimens
Joaquim Bellmunt, MD, PhD
ESMO 2021
PD-L1 as predictor of survival in DANUBE phase III trial in metastatic urothelial carcinoma
Abstract: 708P
ESMO 2021
Andrea Necchi, MD
Novita’ in tema di tumori vescicali dal congresso ESMO…
VESPER, AURA, NABUCCO, NORSE
ESMO 2021
Joaquim Bellmunt, MD, PhD
Mejorando el futuro de los pacientes con cáncer de…
NORSE, VESPER, Phase II Pembrolizumab in combination with sEphB4-HSA (B4)
ESMO 2021
Joaquim Bellmunt, MD, PhD
Descifrando las estrategias para mejorar las…
IMvigor130, AURA, NABUCCO
ESMO 2021
Joaquim Bellmunt, MD, PhD
PDL-1 como predictor de supervivencia en cáncer de…
DANUBE
Peter Goebell, MD
ESMO 2021
Ipilimumab-Nivolumab Möglichkeiten für alternative Regime
Joaquim Bellmunt, MD, PhD
ESMO 2021
PDL-1 como predictor de supervivencia en cáncer de vejiga metastásico. Analizando el estudio fase III DANUBE
Abstract: 708P
ESMO 2021
A. S. Merseburger, S. Chowdhury, N. Shore, E. Efstathiou, A. Bjartell, P. Goebell, M.-O. Grimm
STAMPEDE: Practice changing in high-risk non-metastatic…
ESMO 2021
A. S. Merseburger, E. Efstathiou, S. Chowdhury, N. Shore, A. Bjartell, G.Morgan, P. Goebell, M.-O. Grimm
ARCHES & PEACE-1: From doublets to triplets in mHSPC?
ESMO 2021
E. Efstathiou, A. S. Merseburger, S. Chowdhury, N. Shore, P. Goebell, M.-O. Grimm, A. Bjartell, G. Morgan
COSMIC-021: mCRPC perspectives in later Lines.
A. S. Merseburger, S. Chowdhury, N. Shore, E. Efstathiou, A. Bjartell, P. Goebell, M.-O. Grimm
ESMO 2021
STAMPEDE: Practice changing in high-risk non-metastatic M0 Pca
A. S. Merseburger, E. Efstathiou, S. Chowdhury, N. Shore, A. Bjartell, G.Morgan, P. Goebell, M.-O. Grimm
ESMO 2021
ARCHES & PEACE-1: From doublets to triplets in mHSPC?
E. Efstathiou, A. S. Merseburger, S. Chowdhury, N. Shore, P. Goebell, M.-O. Grimm, A. Bjartell, G. Morgan
ESMO 2021
COSMIC-021: mCRPC perspectives in later Lines.
ESMO 2021
Eleni Efstathiou MD
The game changer: Abiraterone in high risk M0 prostate…
STAMPEDE
ESMO 2021
Simon Chowdhury, MD, PhD
DS7300 - an exciting novel therapy in prostate cancer…
DS-7300
ESMO 2021
Axel S. Merseburger, MD
More data for extending Enzalutamide's label for mHSPC
ARCHES
ESMO 2021
Axel S. Merseburger, MD
Chemo Upront: Consider combination with Abiraterone
PEACE-1
ESMO 2021
Anders Bjartell, MD, PhD
New data change our practice in non-metastatic…
STAMPEDE
ESMO 2021
Anders Bjartell, MD, PhD
Survival benefit with triplet therapy for mHSPC
PEACE-01
ESMO 2021
Anders Bjartell, MD, PhD
Enzalutamide added to ADT shows clear survival benefit…
ARCHES
ESMO 2021
Petros Grivas, MD, PhD
STAMPEDE trial: new standard of care for localized high…
STAMPEDE
Eleni Efstathiou MD
ESMO 2021
The game changer: Abiraterone in high risk M0 prostate cancer
Simon Chowdhury, MD, PhD
ESMO 2021
DS7300 - an exciting novel therapy in prostate cancer and beyond
Abstract: 513O
Axel S. Merseburger, MD
ESMO 2021
More data for extending Enzalutamide's label for mHSPC
Abstract: LBA25
Axel S. Merseburger, MD
ESMO 2021
Chemo Upront: Consider combination with Abiraterone
Abstract: LBA5
Anders Bjartell, MD, PhD
ESMO 2021
New data change our practice in non-metastatic high-risk PC
Anders Bjartell, MD, PhD
ESMO 2021
Enzalutamide added to ADT shows clear survival benefit with longer follow-up in the ARCHES study
Anders Bjartell, MD, PhD
ESMO 2021
Combination therapies and new targeted therapies in advanced prostate cancer
Neal Shore, MD
ESMO 2021
PSMA – RLT is here!
Petros Grivas, MD, PhD
ESMO 2021
STAMPEDE trial: new standard of care for localized high risk prostate cancer (ADT/RT/ABI)
Abstract: LBA4
Eleni Efstathiou MD
ESMO 2021
mHSPC: ADT alone is not enough!
ESMO 2021
Anders Bjartell, MD
PEACE-1 studien visar överlevnadsvinst med trippel…
PEACE-1
ESMO 2021
Eleni Efstathiou, MD
Μεταστατικός ορμόνο ευαίσθητος καρκίνος προστάτη: Η…
PEACE-1, ARCHES
ESMO 2021
Eleni Efstathiou, MD
Σημαντικό όφελος με την προσθήκη άμπιρατερονης Στην…
STAMPEDE
ESMO 2021
Axel S. Merseburger, MD
Ein weiteres Puzzlestück für Zulassungserweiterung von…
ARCHES
ESMO 2021
Axel S. Merseburger, MD
Chemo Upfront: Kombination mit Abiraterone bedenken!
PEACE-1
Anders Bjartell, MD
ESMO 2021
Resultat från STAMPEDE öppnar för ny kombinationsbehandling vid icke metastaserad hormonkänslig prostatacancer
Anders Bjartell, MD
ESMO 2021
PEACE-1 studien visar överlevnadsvinst med trippel behandling vid metastaserad hormonkänslig prostatacancer
Anders Bjartell, MD
ESMO 2021
Längre uppföljningstid I ARCHES-studien visar klar överlevnadsvinst med enzalutamid som tillägg till kastrationsbehandling vi nydiagnostiserad metastaserad hormonkänslig prostatacancer
Anders Bjartell, MD
ESMO 2021
Kombinationsbehandlingar och nya riktade terapier vid avancerad prostatacancer
Peter Goebell, MD
ESMO 2021
Neue vielversprechende Kombination mit Pembro und lu-PSMA
Eleni Efstathiou, MD
ESMO 2021
Μεταστατικός ορμόνο ευαίσθητος καρκίνος προστάτη: Η θεραπεία με lhrh ανάλογα μόνο δεν είναι αρκετή
Eleni Efstathiou, MD
ESMO 2021
Σημαντικό όφελος με την προσθήκη άμπιρατερονης Στην θεραπεία ασθενών με υψηλού ρίσκου τοπικό περιοχικο Καρκίνο προστάτη
Axel S. Merseburger, MD
ESMO 2021
Ein weiteres Puzzlestück für Zulassungserweiterung von Enzalutamide beim mHSPC
Abstract: LBA25
Axel S. Merseburger, MD
ESMO 2021
Chemo Upfront: Kombination mit Abiraterone bedenken!
Abstract: LBA5
Christian Grohé, MD
ESMO 2021
CAR-T-Zell-Therapie auch bei refraktären Karzinompatienten?
Abstract: 9590
Petros Grivas, MD, PhD
ESMO 2021
Covid19 & Cancer: updates from ESMO 2021
Do you need a login? team@onkowissen.de
Für den erfolgreichen Abschluss der Fortbildungsmodule ist die korrekte (mind. 70%) Beantwortung der Lernerfolgskontrolle für das jeweilige Modul verpflichtend.
Jetzt gleich den Fragebogen ausfüllen!
Zu den Fragebögen
Nicht erneut anzeigen
Durch die Eingabe Ihrer individuellen einheitlichen Fortbildungsnummer (EFN) können Sie CME Fortbildungspunkte sammeln. Die bayrische Landesärztekammer erkennt dabei in jedem Fortbildungsmodul pro 45 min Videoeinheit 2 CME Punkte an. Maximal sind pro Fortbildungsmodul 4 CME Punkte möglich. Für den erfolgreichen Abschluss der Fortbildungsmodule ist die korrekte (mind. 70%) Beantwortung der Lernerfolgskontrolle für das jeweilige Modul verpflichtend.
Die Fortbildungseinheiten verteilen sich auf folgende Fortbildungsmodule:
Durch die Eingabe Ihrer individuellen einheitlichen Fortbildungsnummer (EFN) können Sie CME Fortbildungspunkte sammeln. Die bayrische Landesärztekammer erkennt dabei in jedem Fortbildungsmodul pro 45 min Videoeinheit 2 CME Punkte an. Maximal sind pro Fortbildungsmodul 4 CME Punkte möglich. Für den erfolgreichen Abschluss der Fortbildungsmodule ist die korrekte (mind. 70%) Beantwortung der Lernerfolgskontrolle für das jeweilige Modul verpflichtend.
Die Fortbildungseinheiten verteilen sich auf folgende Fortbildungsmodule: